NCT07044427 Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
| NCT ID | NCT07044427 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Heidelberg |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-02-02 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-02-02 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases. In addition to high treatment and care costs for the healthcare system, falls often lead to a decrease of quality of life, a reduction in physical performance and a loss of independence. Despite the high risk, falls in cancer patients have not yet been scientifically investigated in detail. For patients with multiple myeloma in particular, very little data is available on the prevalence, risk factors and effects of falls. In this study, a fall risk assessment is carried out in patients with multiple myeloma. Furthermore, a patient-specific training intervention for fall prevention will be implemented. The aim of the study is to identify possible fall risk factors in multiple myeloma patients and to establish a structured exercise intervention that minimizes the risk of falls and injuries.
Eligibility Criteria
Inclusion Criteria: * Patients with multiple myeloma requiring therapy (at least 6 months of systemic therapy) * ECOG status ≤ 3 * Age ≥18 years * Patients who state that they want to carry out the training program at least 3 times/week and participate in the planned follow-up visits * Ability to give informed consent * Written consent to participate in the study * Sufficient written and spoken German to complete the questionnaire Exclusion Criteria: * Any physical or mental limitations that would prevent participation in the training program or the planned follow-up checks.
Contact & Investigator
Dapunt
STUDY CHAIR
University Hospital Heidelberg
Frequently Asked Questions
Who can join the NCT07044427 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07044427 currently recruiting?
Yes, NCT07044427 is actively recruiting participants. Contact the research team at ulrike.dapunt@med.uni-heidelberg.de for enrollment information.
Where is the NCT07044427 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT07044427 clinical trial?
NCT07044427 is sponsored by University Hospital Heidelberg. The principal investigator is Dapunt at University Hospital Heidelberg. The trial plans to enroll 60 participants.